Dr. Heron brings decades of experience in executive leadership and life sciences research and development to Vaxart's Board Dr. Heron brings decades of experience in executive leadership and life sciences research and development to Vaxart's Board
Here is the original post:
Vaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D. Joins Board of Directors
SAN DIEGO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present a genetic evaluation and an analysis of cognitive function from the Company’s ongoing longitudinal natural history study of people living with classical homocystinuria (HCU), at the Society for the Study of Inborn Errors of Metabolism Annual Symposium in Freiburg, Germany, August 30 – September 2, 2022. Data exploring genomic population-based estimates of the incidence of HCU will also be presented. The Company is currently advancing a novel investigational enzyme replacement therapy, pegtibatinase, for the treatment of HCU.
Originally posted here:
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium
Significant Milestones Achieved Significant Milestones Achieved
See the rest here:
Kane Biotech Announces Second Quarter 2022 Financial Results
SOMERVILLE, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that it will regain full development and commercial rights to FIN-524 (previously known as TAK-524) and FIN-525 from Takeda Pharmaceutical Company Limited (“Takeda”). Following a review of its pipeline, Takeda informed Finch of its decision to terminate its collaboration with Finch, effective November 17, 2022, resulting in the return to Finch of worldwide rights to develop and commercialize FIN-524, FIN-525, and any other microbiome product candidates for inflammatory bowel disease (IBD). FIN-524 and FIN-525 are investigational, orally administered targeted microbiome product candidates composed of bacterial strains selected for their potential immuno-modulatory properties.
Read the original:
Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD
TORONTO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA), the Canadian parent of Blueberries S.A.S. (“BBSAS”), the premier Latin American licensed cultivator and producer of medicinal cannabis and medicinal-grade cannabis extracts, (together the “Company” or "Blueberries"), is pleased to report its financial results for the quarter ended on June 30, 2022. Today, Blueberries has filed its unaudited condensed interim consolidated financial statements and related management's discussion and analysis, both of which are available on Blueberries’ profile at www.sedar.com. All amounts are expressed in Canadian dollars, unless otherwise noted.
See the original post here:
Blueberries Medical Reports 2022 Q2 Financial Results and Provides Corporate and Operations Update
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company addressing tumor recurrence through cell-based immunotherapies, today announces that it has entered into a binding agreement for a financing commitment of up to SEK 200 million (“Transaction”) with Negma Group Ltd, a Paris-based leading financial institution (“Negma”). The Company has also entered into a binding commitment letter to receive a shareholder loan up to SEK 50 million with its existing shareholder Van Herk Investments.
Read the original:
Mendus AB: Mendus announces financing commitments totaling up to SEK 250 million with Van Herk Investments and Negma Group
-- the 7th innovative drug in Junshi Biosciences’ pipeline to get IND approval from the US FDA -- the 7th innovative drug in Junshi Biosciences’ pipeline to get IND approval from the US FDA
Here is the original post:
Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor)
REGULATED INFORMATION
View original post here:
Bone Therapeutics to host Extraordinary General Meeting on 26 September 2022
These authors contributed equally: Andrea Raso, Ellen Dirkx.
Department of Molecular Genetics, Faculty of Science and Engineering, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands
Andrea Raso,Ellen Dirkx,Vasco Sampaio-Pinto,Hamid el Azzouzi,Lara Ottaviani,Serv Olieslagers,Paula A. da Costa Martins&Leon J. De Windt
i3S - Instituto de Investigao e Inovao em Sade, INEB - Instituto Nacional de Engenharia Biomdica, ICBAS - Instituto de Cincias Biomdicas de Abel Salazar, University of Porto, Porto, Portugal
Vasco Sampaio-Pinto&Diana S. Nascimento
Department of Molecular Genetics, Erasmus University MC, Rotterdam, The Netherlands
Hamid el Azzouzi
The Abdus Salam International Centre for Theoretical Physics, Trieste, Italy
Ryan J. Cubero
IST Austria, Klosterneuburg, Austria
Ryan J. Cubero
Stem Cell Institute and Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, MN, USA
Daniel W. Sorensen&Jop H. van Berlo
Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands
Manon M. Huibers&Roel de Weger
Department of Cardiothoracic Surgery, Radboud University Medical Center, Nijmegen, The Netherlands
Sailay Siddiqi&Serena Zacchigna
International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy
Silvia Moimas,Consuelo Torrini,Lorena Zentillin,Luca Braga&Mauro Giacca
Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto, Porto, Portugal
Paula A. da Costa Martins
School of Cardiovascular Medicine and Sciences, Kings College London, London, UK
Mauro Giacca
Read the rest here:
Author Correction: A microRNA program regulates the balance between cardiomyocyte hyperplasia and hypertrophy and stimulates cardiac regeneration -...
When I was diagnosed with multiple myeloma at age 63, it actually didnt bother me. I felt like whatever this was, God had a plan charted for my life before I was even born. Apparently, cancer was meant to be a part of it. So, there was no sense in getting angry or upset about it or throwing myself a big pity party. This was just my lot in life.
I chose MD Anderson for my multiple myeloma treatment because thats what my doctor recommended. But Id already been coming here regularly for prostate cancer screenings. So, I trusted its doctors as medical professionals and experts in cancer treatment. As it turns out, that trust was well-placed. Because Im still here, 10 years later. And, my cancer is still in remission.
Surprise multiple myeloma diagnosis leads to first round of treatment
By the time I was diagnosed, my disease was not considered curable. Multiple myeloma has only three stages, and I was in the final one. Id experienced no symptoms, save a little back pain. But an X-ray showed cancerous lesions all over my spine and rib cage. Two of my vertebrae had cracked because the cancer was growing through the bone.
Myeloma specialist Dr. Michael Wang recommended a stem cell transplant under Dr. Betul Oran. But first, Id need two weeks of radiation therapy under radiation oncologist Dr. Chelsea Pinnix, to treat the lesions on my spine, and several rounds of a chemotherapy drug called bortezomib to prepare my body for the stem cell transplant.
Multiple myeloma relapse leads to clinical trial
I had a stem cell transplant using my own cells on July 9, 2013. Recovery was rough. I ended up back in the hospital the next two Christmases in a row for various issues. But after that, I finally started getting better.
Unfortunately, my cancer relapsed just a few years later. But Dr. Wang said I was a good candidate for a clinical trial involving a new targeted therapy drug now called daratumumab. If I joined it, Id get an infusion of that drug once a month, then take an oral chemotherapy drug called pomalidomide once every other day for 21 days out of each month.
I thought about all the people who have cancer, and how some of them can deal with it pretty well and others cant. I felt like me having this disease might be an opportunity for doctors to study it more closely and possibly find a cure. So, if I could help out with that process, I wanted to do it.
Life after a stem cell transplant and a targeted therapy clinical trial
I joined the clinical trial in September 2015. It went really well, and the experimental treatment I received put me back in remission within a year.
I still have a little weakness in my arms and legs. And Im taking a different course of drugs today due to another relapse. I may have to keep taking it for the rest of my life. But thats OK.
I dont get around as easily as Id like to anymore, but Im alive and able to do most of the things I want to do. When I was diagnosed in 2012, the life expectancy for someone with multiple myeloma was only five years. And here I am, still around after 10 years.
I havent completely recovered because multiple myeloma isnt my only issue. I also have diabetes, heart problems, high blood pressure and sometimes deep vein thrombosis, or dangerous blood clots. But I have a team of specialists at MD Anderson who help me manage all of those conditions. I see endocrinologist Dr. Sonali Thosani, cardiologists Dr. Kaveh Karimzad and Dr. Cezar Iliescu and hematolologist Dr. Cristiam Rojas Hernandez.
I also see multiple myeloma specialist Dr. Elisabet Manasanch now instead of Dr. Wang, because he shifted his practice to focus on a very specific subtype of cancer thats different from mine. I really hated to lose him, because Dr. Wang was great. But all of the doctors and staff Ive met at MD Anderson have been wonderful.And I am grateful for the care of both Dr. Wang and Dr. Manasanch.
I believe if my lifes journey were finished, then I would be finished, too. So, I must not have done everything Im supposed to do just yet. I am grateful to both God and MD Anderson for giving me more time to meet my goals, because I know with their help, I will.
Request an appointment at MD Anderson online or by calling 1-877-632-6789.
See original here:
10-year multiple myeloma survivor: Why I joined a clinical trial at MD Anderson - MD Anderson Cancer Center